Chimeric Therapeutics is trading 20% down at A$0.00, with no clear catalyst identified for the September 29 move.

  • The latest major company development located was the August 19 halt to enrollment and dosing in the CHM-2101 trial after dose-limiting toxicities; it predates this move and does not establish its cause.
  • A recent company post noted a $1.62M advance on its FY2026 R&D tax incentive, but no source connected it to the price change.